These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11137101)

  • 1. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients.
    Morishita E; Asakura H; Saito M; Yamazaki M; Ontachi Y; Mizutani T; Kato M; Matsuda T; Nakao S
    Atherosclerosis; 2001 Jan; 154(1):203-12. PubMed ID: 11137101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease.
    Morishita E; Hashimoto T; Asakura H; Saito M; Yamazaki M; Aoshima K; Yoshida T; Kato H; Matsuda T
    Thromb Haemost; 1998 May; 79(5):919-23. PubMed ID: 9609221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
    Zitoun D; Bara L; Basdevant A; Samama MM
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):77-81. PubMed ID: 8548430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma.
    Hansen JB; Huseby NE; Sandset PM; Svensson B; Lyngmo V; Nordøy A
    Arterioscler Thromb; 1994 Feb; 14(2):223-9. PubMed ID: 8305412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
    Mitropoulos KA; Armitage JM; Collins R; Meade TW; Reeves BE; Wallendszus KR; Wilson SS; Lawson A; Peto R
    Eur Heart J; 1997 Feb; 18(2):235-41. PubMed ID: 9043839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys.
    Abumiya T; Nakamura S; Takenaka A; Takenaka O; Yoshikuni Y; Miyamoto S; Kimura T; Enjyoji K; Kato H
    Arterioscler Thromb; 1994 Mar; 14(3):483-8. PubMed ID: 8123656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men.
    Hansen JB; Grimsgaard S; Huseby N; Sandset PM; Bønaa KH
    Thromb Res; 2001 Apr; 102(1):3-13. PubMed ID: 11323009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction.
    Lorena M; Perolini S; Casazza F; Milani M; Cimminiello C
    Thromb Res; 1997 Aug; 87(4):397-403. PubMed ID: 9271817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
    Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
    Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
    Thiery J; Creutzfeldt C; Creutzfeldt W; Walli AK; Seidel D
    Klin Wochenschr; 1990 Aug; 68(16):814-22. PubMed ID: 2214604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease.
    Berrettini M; Parise P; Ricotta S; Iorio A; Peirone C; Nenci GG
    Thromb Haemost; 1996 Mar; 75(3):395-400. PubMed ID: 8701396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocyte tissue factor response is decreased in patients with hyperlipidemia.
    Rugeri L; Susen S; Bard JM; Corseaux D; Gavériaux V; Devos P; Lecerf JM; Duriez P; Jude B
    Thromb Res; 1999 Nov; 96(4):283-92. PubMed ID: 10593431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a 'procoagulant state': effects of bezafibrate therapy.
    Jonkers IJ; de Man FH; van Tilburg NH; van der Laarse A; Sandset PM; Smelt AH; Bertina RM
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):705-12. PubMed ID: 11734672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia.
    Hansen JB; Huseby KR; Huseby NE; Sandset PM; Hanssen TA; Nordøy A
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):879-85. PubMed ID: 7600119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.
    Szczeklik A; Musiał J; Undas A; Gajewski P; Góra P; Swadźba J; Jankowski M
    J Am Coll Cardiol; 1999 Apr; 33(5):1286-93. PubMed ID: 10193729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of monthly atorvastatin treatment on hemostasis.
    Okopien B; Krysiak R; Herman ZS
    Int J Clin Pharmacol Ther; 2004 Nov; 42(11):589-93. PubMed ID: 15598024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders.
    Ozcan MA; Cömlekçi A; Demirkan F; Yüksel F; Sari I; Demir T; Ozsan GH; Orük G; Yeşil S; Undar B
    Thromb Res; 2003 Jun; 110(4):243-7. PubMed ID: 14512089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.